(IN BRIEF) AstraZeneca reported positive Phase III Bax24 trial results showing that baxdrostat achieved a significant and clinically meaningful reduction in 24-hour ambulatory systolic blood pressure in patients with treatment-resistant hypertension. The once-daily oral therapy was well tolerated and maintained … Read the full press release
Posted in Business, Healthcare, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged Advancing Toward Regulatory Submission, AHA 2025, aldosterone, aldosterone synthase inhibitor, ambulatory blood pressure, American Heart Association, AstraZeneca, AstraZeneca’s Baxdrostat Achieves Significant Blood Pressure Reduction in Phase III Bax24 Trial, AstraZeneca’s Baxdrostat Achieves Strong Blood Pressure Reduction in Phase III Bax24 Trial for Resistant Hypertension, Bax24, Baxdrostat, Baxdrostat Delivers Significant 24-Hour Blood Pressure Control in Phase III Study, BaxHTN, Bryan Williams, cardiovascular health, Chronic kidney disease, clinical trial, heart failure prevention, Hypertension Treatment, Phase III results, primary aldosteronism, resistant hypertension, rHTN, SBP, Sharon Barr, systolic blood pressure
(IN BRIEF) Roche and Alnylam have entered into a partnership to jointly develop and commercialize zilebesiran, an investigational RNAi therapeutic for the treatment of hypertension. Hypertension affects a significant number of adults worldwide and is a major risk factor for … Read the full press release
Posted in Business, Healthcare, Industrial, Management, News, Pharma & Biotech, Science, Switzerland
Tagged Alnylam, Hypertension Treatment, partnership, RNAi Therapy, Roche, Teresa Graham, Yvonne Greenstreet MBChB, zilebesiran
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?